Taurine for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Taurine for Health & Longevity

Created on 08/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Taurine is a sulfur compound from seafood and meat. Controlled human trials show modest improvements in blood pressure, blood sugar, blood fats and inflammation markers, largest where starting values are abnormal, minimal where normal. Longer-life claims rest entirely on animals. Safety is unusually good at the doses studied; the main hazards arise on top of blood-pressure or blood-sugar medication. (Full Review)

Protocol

Standard longevity-oriented dose
1.5–3 g daily
Pure taurine powder or capsules; the range pooled trial data identify as most effective for blood pressure, glucose and lipid endpoints.
Split dosing
Twice or thrice daily
Plasma half-life is near one hour, so divided dosing maintains exposure better than a single bolus for cardiometabolic goals.
Best time of day
With meals
With meals for cardiometabolic use, since food reduces gastrointestinal intolerance; evening dosing suits calming use, pre-workout timing suits performance.
Time to effect
Blood pressure
2–4 weeks
Blood pressure and inflammation markers shift within the first two to four weeks.
Glucose and lipids
8+ weeks
Pooled analyses found durations under eight weeks insufficient for these outcomes.
Acute performance
~1 hour
Acute performance effects appear within one hour.

Benefits

Contraindications
  • Advanced chronic kidney disease (estimated filtration rate below 30 mL/min/1.73 m², or dialysis)
  • Known sulfite or sulfonamide hypersensitivity (any dose above 200 mg)
  • Active haematologic malignancy (particularly acute myeloid leukaemia)
  • Symptomatic hypotension, or resting systolic pressure persistently below 100 mmHg
  • Pregnancy and lactation (supplemental doses above roughly 400 mg)
    •
Key Interactions
  • Antihypertensive drugs: ACE inhibitors (lisinopril), ARBs (losartan), calcium channel blockers (amlodipine), diuretics (hydrochlorothiazide)
  • Glucose-lowering drugs: insulin, sulfonylureas (glipizide, glyburide), SGLT2 inhibitors (empagliflozin)
  • Lithium
  • Over-the-counter caffeine and energy products
  • Over-the-counter nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen
  • Blood-pressure-lowering supplements: magnesium, potassium, dietary nitrate (beetroot), garlic extract, hibiscus, omega-3 fatty acids
  • Beta-alanine
  • Other interventions: endurance exercise, calorie restriction, rapamycin

Risk & Side Effects

  • High: Additive blood-pressure lowering
    •
  • Medium: Gastrointestinal intolerance; additive glucose lowering
    •
  • Low: Hypersensitivity in sulfur-sensitive individuals; accumulation in advanced kidney disease
  • Speculative: Fuelling of established malignancy; downregulation of endogenous synthesis

Monitoring

Marker Target Why
Seated blood pressure 110–120 / 70–78 mmHg The most reliably responsive endpoint
Fasting glucose 75–86 mg/dL Captures the glycaemic effect
HbA1c 4.8–5.3% Averages glucose over ~3 months
Fasting insulin 2–5 µIU/mL Detects insulin resistance before glucose rises
Triglycerides Below 80 mg/dL The lipid fraction most responsive to taurine
LDL-C Below 100 mg/dL Confirms whether the modest cholesterol effect matters
hs-CRP Below 0.8 mg/L Tracks the inflammation signal
ALT and AST ALT below 20 U/L (women) or 25 U/L (men) Detects the liver enzyme effect
Creatinine with estimated filtration rate Above 90 mL/min/1.73 m² Renal clearance is taurine's only elimination route
Plasma taurine No established target; track change from personal baseline Confirms absorption in low-status individuals

Cadence: Blood pressure weekly for the first four weeks, then monthly; metabolic and lipid panels at 12 weeks, then every 6–12 months; kidney function annually.

Qualitative Assessment

  • Lightheadedness on standing, the earliest sign of additive blood-pressure lowering
  • Perceived exertion and time to exhaustion during a repeated benchmark workout
  • Upper abdominal discomfort, bloating or stool looseness in the first two weeks
  • Sleep latency and subjective calm, if taurine is dosed in the evening
  • Energy stability across the afternoon, which tracks loosely with glycaemic change
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.